06 November 2023
06 November 2023
The FDA guidance to provide clarity for sponsors running trials during war, disaster and PHE is released but questions remain.
Conjunctival haemorrhage, higher intraocular pressure and choroidal neovascularisation were the TEAEs reported in the trial.
Celldex will initiate a Phase II trial with barzolvolimab in PN in early 2024.
In the trial, BI 690517 plus empagliflozin offered up to a 39.5% decline in albuminuria versus placebo.
The company is currently raising seed funding for the LCGA-17 peptide programme, with plans to start trials in H1 2024.
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
The trial will be carried out at up to 56 trial sites enrolling 387 subjects.
ABBV-RGX-314 lowered vision-threatening incidents by 89% when compared to control group.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
